Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford University’s Professor Teresa Lambe, the designer of the vaccine, fears Marburg disease is ‘now being seen in places where it’s never been seen before’

A promising Marburg vaccine developed by the same Oxford scientists behind the Covid-19 jab has yet to be tested in humans due to a lack of funding.

Professor Teresa Lambe, a vaccinologist at the University of Oxford, said Marburg virus is “now being seen in places where it’s never been seen before,” citing West Africa and, specifically, Ghana, which declared its first-ever outbreak earlier this month.

There are no vaccines against the virus, which can kill up to 88 per cent of people it infects, and nor are there any treatments available.

Prof Lambe and her team have developed a vaccine which appears to generate a “good immune response” in animals, but they are unable to test the jab in human trials because of limited funding.

“We’ve been able to get money to progress this to a stage where we can make a product that is ready to go in people’s arms,” she told The Independent. “But we haven’t yet got any money to get the vaccine into clinical trial.

“That’s certainly something that we will be looking to do as soon as we’ve got the vaccine ready. This speaks to the whole field where we’re able to make these vaccines, but there isn’t funding that will allow us to test these vaccines or get them across the finish line.”

Read the full story on the Department of Paediatrics website. 

Similar stories

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

Early life infection increases sensitivity to pain in newborn babies

Researchers from Oxford’s Department of Paediatrics have discovered that infection can increase a baby’s sensitivity to pain, which may last longer than the infection.

Oxford expands the Cartography collaboration with Janssen

The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Oxford scientist named Australian of the Year in the UK

The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.

Typhoid vaccine over 81% effective in tackling disease in Nepal

A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.